German biomarker services company Targos Molecular Pathology and WuXi PharmaTech, a Chinese pharmaceutical, biotechnology and medical device R&D services company, Friday announced their collaboration on the validation and analysis of clinical tissue biomarkers in cancer.
Work related to the collaboration will begin immediately, Targos spokesman George Kumar told Device Daily Bulletin.
Under the agreement, Targos will provide education and training to support WuXi pathologists and histotechnologists in generating accurate, objective and reproducible diagnostic results. Targos will also use WuXi laboratory facilities to conduct clinical trial work and pathology training in China, Kumar said.
Moreover, Targos will provide quality standards, know-how and services to support WuXi's bioanalytical work for pharmaceutical customers, the companies said. The addition of Targos’ molecular pathology testing services will allow WuXi to provide its customers with a complete platform of services in soluble, cell and tissue biomarkers, the companies added.
Targos is looking to India for future collaboration. The company will be training seven Indian pathologists in its Kassel, Germany, facility this July, Kumar said. — Kellen Owings
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.